Effect of 5-HT1A receptor-mediated serotonin augmentation on Fos immunoreactivity in rat brain

European Journal of Pharmacology

Volumn 455, Issue 2-3, 2002, Pages 109-115

  Jongsma, Minke E ^a   Sebens, Jantiena B ^b   Bosker, Fokko J ^a   Korf, Jakob ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

5 HT1A receptor; Antidepressant; C fos; Citalopram; Hypothalamic pituitary adrenal axis; WAY 100635

Indexed keywords

CITALOPRAM; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PROTEIN FOS; SEROTONIN; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SODIUM CHLORIDE; PIPERAZINE DERIVATIVE; PROTEIN C FOS; PYRIDINE DERIVATIVE; SEROTONIN 1 RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ACTIVITY; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION; HISTOLOGY; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS; HYPOTHALAMUS VENTROMEDIAL NUCLEUS; IMMUNOREACTIVITY; LIMBIC SYSTEM; MALE; NERVE CELL; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SEROTONIN RELEASE; STAINING; THALAMUS MIDLINE NUCLEUS; ANIMAL; BIOSYNTHESIS; BRAIN; IMMUNOHISTOCHEMISTRY; METABOLISM; PHYSIOLOGY; SECRETION; WISTAR RAT;

ANIMALS; BRAIN; CITALOPRAM; DRUG SYNERGISM; IMMUNOHISTOCHEMISTRY; MALE; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-FOS; PYRIDINES; RATS; RATS, WISTAR; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0037195598     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02583-9     Document Type: Article

References (39)

1. Barden N., Reul J.M., Holsboer F. Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends Neurosci. 18:1995;6-11.
2. Blier P., De Montigny C., Chaput Y. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J. Clin. Psychopharmacol. 7:1987;24S-35S.
3. Blier P., De Montigny C., Tardif D. Short-term lithium treatment enhances responsiveness of postsynaptic 5-HT(1A) receptors without altering 5-HT autoreceptor sensitivity: an electrophysiological study in the rat brain. Synapse. 1:1987;225-232.
4. Chen G., Hasanat K.A., Bebchuk J.M., Moore G.J., Glitz D., Manji H.K. Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants. Psychosom. Med. 61:1999;599-617.
5. 1A receptor agonist flesinoxan enhances Fos immunoreactivity in rat central nucleus of the amygdala, bed nucleus of the stria terminalis and hypothalamus. Eur. J. Neurosci. 8:1996;2340-2347.
6. Cremers T.I., Spoelstra E.N., De Boer P., Bosker F.J., Mork A., Den Boer J.A., Westerink B.H., Wikstrom H.V. Desensitisation of 5-HT autoreceptors upon pharmacokinetically monitored chronic treatment with citalopram. Eur. J. Pharmacol. 397:2000;351-357.
7. Cremers T.I., De Boer P., Liao Y., Bosker F.J., Den Boer J.A., Westerink B.H., Wikstrom H.V. Augmentation with a 5-HT(1A), but not a 5-HT(1B) receptor antagonist critically depends on the dose of citalopram. Eur. J. Pharmacol. 397:2000;63-74.
8. Feldman S., Conforti N., Saphier D. The preoptic area and bed nucleus of the stria terminalis are involved in the effects of the amygdala on adrenocortical secretion. Neuroscience. 37:1990;775-779.
9. Feldman S., Conforti N., Itzik A., Weidenfeld J. Differential effect of amygdaloid lesions on CRF-41, ACTH and corticosteron responses following neural stimuli. Brain Res. 658:1994;21-26.
10. Gray T.S., Carney M.E., Magnuson D.J. Direct projections from the central amygdaloid nucleus to the hypothalamic paraventricular nucleus: possible role in stress-induced adrenocorticotropin release. Neuroendocrinology. 50:1989;433-446.
11. Gundlah C., Hjorth S., Auerbach S.B. Autoreceptor antagonists enhance the effect of the reuptake inhibitor citalopram on extracellular 5-HT: this effect persists after repeated citalopram treatment. Neuropharmacology. 36:1997;475-482.
12. 1A receptor ligands on Fos-like immunoreactivity in rat brain: evidence for activation of noradrenergic transmission. Synapse. 34:1999;145-153.
13. Hjorth S. Serotonin 5-HT1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: a microdialysis study. J. Neurochem. 60:1993;776-779.
14. Holsboer F., Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr. Rev. 17:1996;187-205.
15. Hughes P., Dragunow M. Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system. Pharmacol. Rev. 47:1995;133-178.
16. Javed A., Van De Kar L.D., Gray T.S. p-Chlorophenylalanine and fluoxetine inhibit D-fenfluramine-induced c-Fos expression in the paraventricular nucleus, cingulate cortex and frontal cortex but not in other forebrain and brainstem regions. Brain Res. 774:1997;94-105.
17. Javed A., Van De Kar L.D., Gray T.S. The 5-HT1A and 5-HT2A/2C receptor antagonists WAY-100635 and ritanserin do not attenuate D-fenfluramine-induced c-Fos expression in the brain. Brain Res. 791:1998;67-74.
18. Kilpatrick G.J., Jones B.J., Tyers M.B. Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature. 330:1987;746-748.
19. Leslie R.A., Moorman J.M., Coulson A., Grahame-Smith D.G. Serotonin 2/1C receptor activation causes a localized expression of the immediate-early gene c-Fos in rat brain: evidence for involvement of dorsal raphe nucleus projection fibres. Neuroscience. 53:1993;457-463.
20. Li B.H., Rowland N.E. Effect of chronic dexfenfluramine on c-Fos in rat brain. Brain Res. 728:1996;188-192.
21. Moorman J.M., Leslie R.A. p-Chloroamphetamine induces c-Fos in rat brain: a study of serotonin 2A/2C receptor function. Neuroscience. 72:1996;129-139.
22. Moorman J.M., Jackson A., Grahame-Smith D.G., Leslie R.A. Induction of c-Fos in rat forebrain by pharmacological manipulation of 5-hydroxytryptamine levels. Neuroscience. 68:1995;1089-1096.
23. Morilak D.A., Garlow S.J., Ciaranello R.D. Immunocytochemical localization and description of neurons expressing serotonin 2 receptors in the rat brain. Neuroscience. 54:1993;701-717.
24. Pazos A., Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain: I. Serotonin-1 receptors. Brain Res. 346:1985;205-230.
25. Pazos A., Cortes R., Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain: II. Serotonin-2 receptors. Brain Res. 346:1985;231-249.
26. Richard D., Rivest S., Rivier C. The 5-hydroxytryptamine agonist fenfluramine increases c-Fos-like immunoreactivity in the brain. Brain Res. 594:1992;131-137.
27. Rollema H., Clarke T., Sprouse J.S., Schulz D.W. Combined administration of a 5-hydroxytryptamine (5-HT)1D antagonist and a 5-HT reuptake inhibitor synergistically increases 5-HT release in guinea pig hypothalamus in vivo. J. Neurochem. 67:1996;2204-2207.
28. Romero L., Hervas I., Artigas F. The 5-HT1A antagonist WAY-100635 selectively potentiates the presynaptic effects of serotonergic antidepressants in rat brain. Neurosci. Lett. 219:1996;123-126.
29. Sebens J.B., Koch T., Ter Horst G.J., Korf J. Differential c-Fos-protein induction in rat forebrain regions after acute and long-term haloperidol and clozapine treatment. Eur. J. Pharmacol. 273:1995;175-182.
30. Sebens J.B., Kuipers S.D., Koch T., Ter Horst G.J., Korf J. Limited participation of 5-HT(1A) and 5-HT(2A/2C) receptors in the clozapine-induced c-Fos-protein expression in rat forebrain regions. Eur. J. Pharmacol. 408:2000;11-17.
31. Sharp T., Umbers V., Gartside S.E. Effect of a selective 5-HT reuptake inhibitor in combination with 5-HT1A and 5-HT1B receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo. Br. J. Pharmacol. 121:1997;941-946.
32. Sheng M., Greenberg M.E. The regulation and function of c-Fos and other immediate early genes in the nervous system. Neuron. 4:1990;477-485.
33. Sheng M., McFadden G., Greenberg M.E. Membrane depolarization and calcium induce c-Fos transcription via phosphorylation of transcription factor CREB. Neuron. 4:1990;571-582.
34. Sheng M., Thompson M.A., Greenberg M.E. CREB: a Ca(2+)-regulated transcription factor phosphorylated by calmodulin-dependent kinases. Science. 252:1991;1427-1430.
35. Steinbusch H.W. Distribution of serotonin-immunoreactivity in the central nervous system of the rat-cell bodies and terminals. Neuroscience. 6:1981;557-618.
36. Stephenson C.P., Hunt G.E., Topple A.N., McGregor I.S. The distribution of 3,4-methylenedioxymethamphetamine "Ecstasy"-induced c-Fos expression in rat brain. Neuroscience. 92:1999;1011-1023.
37. Suemaru S., Darlington D.N., Akana S.F., Cascio C.S., Dallman M.F. Ventromedial hypothalamic lesions inhibit corticosteroid feedback regulation of basal ACTH during the trough of the circadian rhythm. Neuroendocrinology. 61:1995;453-463.
38. Uphouse L. Multiple serotonin receptors: too many, not enough, or just the right number? Neurosci. Biobehav. Rev. 21:1997;679-698.
39. Veening J.G., Coolen L.M., Spooren W.J., Joosten H., van Oorschot R., Mos J., Ronken E., Olivier B. Patterns of c-Fos expression induced by fluvoxamine are different after acute vs. chronic oral administration. Eur. Neuropsychopharmacol. 8:1998;213-226.